Digital Look

Welcome to Digital Look++,
you are not logged in

Futura Medical (FUM)

Pharma and Biotech

2.86p

Trade now with Barclays Stockbrokers

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
30-Jun-25	Interim	1.00	(6.69)	(2.17)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	n/a	(2.93)	(0.99)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	n/a	(5.87)	(1.83)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	n/a	(6.87)	(2.03)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	3.10	(6.89)	(2.21)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	13.93	1.29	0.43p	73.6	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-25	5.04	(3.59)	(1.14)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-26	5.10	(2.58)	(0.75)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-27	6.57	(0.69)	(0.22)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	73.60	73.60	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.